Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)
Wuhan, CN
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. specializes in the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) reagents and related equipment. Their extensive product line features molecular diagnostics, including genetic tests for drug metabolism and pathogen nucleic acid detection kits, alongside immunodiagnostic and blood gas analysis solutions. Beyond diagnostics, the company delivers comprehensive information solutions for emergency and critical illness, which encompass specialized software, supporting hardware, and expert certification consulting. They also provide third-party medical testing services. These offerings are applied across a broad spectrum of medical fields, addressing conditions such as cardiovascular, kidney, infectious, diabetes, endocrine, and metabolic diseases, as well as obstetrics and gynecology. Furthermore, their products support prenatal and postnatal care, general health check-ups, and specific analyses for thyroid function, hormones, blood gases, coagulation, drug metabolism, and pathogen identification. Established in 2008, the company is headquartered in Wuhan, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25% | -3.35% | -6.04% | -15.31% | -16.20% | -17.21% | -17.38% | -48.86% | -50.94% | +67.51% | +67.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-24.3% Q1'26: +1.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-120.6% Q1'26: +91.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-38.2% Q1'26: +209.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-23.9% Q1'26: -18.8% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-1.3% Q1'26: -2.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+7.0% Q1'26: +19.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.58× Q1'26: -0.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
95.34M
est: 100.00M (-4.7%)
|
140.98M
est: 150.00M (-6.0%)
|
165.12M
est: 225.00M (-26.6%)
|
176.38M
est: 194.00M (-9.1%)
|
181.16M
est: 225.00M (-19.5%)
|
959.10M
est: 259.00M (+270.3%)
|
2.83B
est.
|
2.83B
est: 8.22B (-65.6%)
|
10.53B
est: 4.34B (+142.5%)
|
749.54M
est: 4.34B (-82.7%)
|
350.06M
est: 3.01B (-88.4%)
|
| EBITDA |
43.10M
est: 46.39M (-7.1%)
|
73.43M
est: 69.59M (+5.5%)
|
84.99M
est: 104.38M (-18.6%)
|
84.39M
est: 90.00M (-6.2%)
|
63.43M
est: 104.38M (-39.2%)
|
574.59M
est: 120.15M (+378.2%)
|
1.31B
est.
|
1.72B
est: 3.81B (-54.9%)
|
5.12B
est: 2.01B (+154.4%)
|
216.80M
est: 2.01B (-89.2%)
|
90.96M
est: 969.61M (-90.6%)
|
| EBIT |
41.53M
est: 39.58M (+4.9%)
|
69.16M
est: 59.37M (+16.5%)
|
75.43M
est: 89.06M (-15.3%)
|
71.20M
est: 76.79M (-7.3%)
|
46.65M
est: 89.06M (-47.6%)
|
557.36M
est: 102.52M (+443.7%)
|
1.12B
est.
|
1.70B
est: 3.25B (-47.8%)
|
5.08B
est: 1.72B (+195.6%)
|
150.39M
est: 1.72B (-91.2%)
|
33.91M
est: 687.29M (-95.1%)
|
| Net Income |
35.60M
est: 50.22M (-29.1%)
|
59.69M
est: 76.04M (-21.5%)
|
65.49M
est: 113.35M (-42.2%)
|
61.42M
est: 101.87M (-39.7%)
|
41.53M
est: 115.50M (-64.0%)
|
468.93M
est: 131.28M (+257.2%)
|
1.49B
est.
|
1.41B
est: 3.96B (-64.3%)
|
4.21B
est: 2.09B (+101.3%)
|
74.93M
est: 2.09B (-96.4%)
|
74.52M
est: 1.51B (-95.1%)
|
| SGA |
33.02M
est: 12.02M (+174.8%)
|
52.30M
est: 18.02M (+190.2%)
|
38.59M
est: 27.03M (+42.8%)
|
50.50M
est: 23.31M (+116.6%)
|
63.76M
est: 27.03M (+135.9%)
|
122.84M
est: 31.12M (+294.7%)
|
340.03M
est.
|
273.23M
est: 987.52M (-72.3%)
|
591.45M
est: 521.69M (+13.4%)
|
218.97M
est: 521.69M (-58.0%)
|
165.41M
est: 673.40M (-75.4%)
|
| EPS |
0.23
est: 0.23 (+2.1%)
|
0.39
est: 0.34 (+14.4%)
|
0.42
est: 0.51 (-17.4%)
|
0.35
est: 0.46 (-23.4%)
|
0.20
est: 0.52 (-61.4%)
|
2.25
est: 0.59 (+282.1%)
|
6.68
est.
|
6.68
est: 17.78 (-62.4%)
|
18.46
est: 9.38 (+96.9%)
|
0.33
est: 9.38 (-96.5%)
|
0.33
est: 6.25 (-94.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 34.1K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaohui Li | Accounting Supervisor | — | — |
| Chen Li Li | Chairman & GM | — | female |
| Rui Wang | Deputy GM, Chief Financial Officer & Board Secretary | — | male |
| Wang Ying | Vice Chairman & Deputy GM | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002932.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
